Canaccord Maintains Buy Rating and $43.50 PT on Arthocare

A report from Canaccord reiterates its Buy rating and $43.50 price target on Arthocare ARTC. The report states, “ArthroCare announced it had reached a preliminary settlement agreement for its outstanding shareholder class action lawsuits for $74M. We believe investors will view this positively as it removes one of the major remaining legal headwinds for the company, leaving the DOJ as the last legal overhang.” ARTC closed yesterday at $25.56.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorNewsReiterationLegalAnalyst RatingsCanaccord
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!